MC1This drug works for PNPO patients. If a patient misses a dose of MC1, they have a seizure. And could die. Why? Because MC1 consists of the vitamin B varient they are lacking. This disease was only diagnozed 12 years ago and why it has been brought to Medicures attention. If succesful with the FDA fast track testing, the Voucher Medicue will recieve could be worth 100-200 million US dollars. This voucher can be sold to other pharmaceutical companies so they can fast track a new drug that normally takes years for approval. It is this incentive why companies invest in new drugs that help few patients around the world. And why America is such a great country. However, the FDA approval is still not a gimmee.
Friesen is buying on the open market. I suspect the odds are in his favor.
10,000,000 shares...low ball $100,000,000 = $10 gain in earnings per share